NCT07255001Recruiting
Using Strength Tests to Better Understand How Pancreatic Cancer Affects Muscle Mass and Quality of Life
Monitoring Physical Function Changes for Patients Living With Pancreatic Ductal Adenocarcinoma: Potential for Better Understanding of Treatment Trajectory and Survival
Source: ClinicalTrials.gov · Last updated 15 Sept 2026
Brief summary (registry, in English)
The goal of this clinical trial is to measure hand grip strength in adults with pancreatic ductal adenocarcinoma (PDAC). The main questions it aims to answer are: * Is it feasible to measure hand grip strength as part of a clinic visit? * Are changes in hand grip strength related to changes in body composition? * Is hand grip strength related to a person's well-being? * Is hand grip strength related to how a tumour responds to treatment? Participants will squeeze a device with their hand to measure their hand grip strength and complete questionnaires about their well-being when they are seen in clinic for their regular medical care for PDAC.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 2 Sept 2025
- Start date
- 13 Aug 2026
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- British Columbia Cancer Agency
- Diseases
- Pancreatic cancer
- NCT number
- NCT07255001
What you commit to
- Study type: Interventional
- Planned participants: 50
- From 13 Aug 2026 to the primary completion date, 31 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Individuals with CT imaging performed outside of Vancouver, BC, Canada.
- Individuals who are unfit to undergo CT imaging of the third lumbar vertebra (L3).
- Individuals who are currently participating in a structured moderate intensity resistance training program.
- Individuals who are otherwise judged by the investigator to be unfit to proceed with this protocol.
- Unable to comply with study assessments and follow-up.
Who the study is looking for
- Age 18 years or older.
- Histological and/or radiological diagnosis of resectable, non-resectable, or metastatic PDAC. For resectable PDAC, adjuvant setting only.
- ECOG performance status 0-2.
- Life expectancy greater than 6 months as judged by the investigator.
- Planned for treatment, either as part of routine care or in combination with an investigational agent within another study.
- Ability to hold a dynamometer with one hand.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| BC Cancer Coordinator of this site? Confirm its status | Vancouver | Canada | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.